Loading...
Docoh

Aclaris Therapeutics (ACRS)

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Company profile

Ticker
ACRS
Exchange
CEO
Neal Walker
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Aclaris Therapeutics International Limited • Aclaris Life Sciences, Inc. • Confluence Discovery Technologies, Inc. ...

ACRS stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

3 Aug 22
3 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 68.26M 68.26M 68.26M 68.26M 68.26M 68.26M
Cash burn (monthly) (no burn) 3.77M 7M 6.92M 6.56M 5.69M
Cash used (since last report) n/a 11.77M 21.88M 21.65M 20.5M 17.8M
Cash remaining n/a 56.49M 46.38M 46.61M 47.77M 50.46M
Runway (months of cash) n/a 15.0 6.6 6.7 7.3 8.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 22 Douglas J. Manion RSU Common Stock Grant Acquire A No No 0 62,300 0 62,300
1 Aug 22 Douglas J. Manion Employee Stock Option Common Stock Grant Acquire A No No 13.62 217,800 2.97M 217,800
1 Jul 22 Cawkwell Gail RSU Common Stock Grant Acquire A No No 0 60,000 0 60,000
1 Jul 22 Cawkwell Gail Employee Stock Option Common Stock Grant Acquire A No No 13.83 210,000 2.9M 210,000
17 Jun 22 Andrew N Schiff Common Stock Sell Dispose S No Yes 15.1428 19,565 296.27K 0
13F holders Current Prev Q Change
Total holders 118 115 +2.6%
Opened positions 16 12 +33.3%
Closed positions 13 32 -59.4%
Increased positions 48 37 +29.7%
Reduced positions 27 43 -37.2%
13F shares Current Prev Q Change
Total value 3.95B 1.11B +254.1%
Total shares 70.54M 66.66M +5.8%
Total puts 13.9K 10.9K +27.5%
Total calls 12.6K 12.2K +3.3%
Total put/call ratio 1.1 0.9 +23.5%
Largest owners Shares Value Change
Wellington Management 4.9M $68.42M -14.5%
BLK Blackrock 4.67M $65.19M +17.1%
VR Adviser 4.56M $63.71M 0.0%
Ra Capital Management 4.4M $61.4M +142.0%
BVF 3.98M $55.51M 0.0%
Rock Springs Capital Management 3.93M $54.82M +1.6%
Biotechnology Value Fund L P 3.87M $42.05M 0.0%
Foresite Capital Fund III 3.4M $49.42M 0.0%
Vanguard 2.81M $39.28M +3.1%
Foresite Capital Management IV 2.81M $39.2M -3.1%
Largest transactions Shares Bought/sold Change
Ra Capital Management 4.4M +2.58M +142.0%
Wellington Management 4.9M -828.99K -14.5%
Orbimed Advisors 2.33M +745.6K +47.2%
BLK Blackrock 4.67M +682.81K +17.1%
Woodline Partners 621.56K +621.56K NEW
Point72 Asset Management 1.73M -543.2K -23.9%
JPM JPMorgan Chase & Co. 461.6K +416.95K +933.8%
Parkman Healthcare Partners 304.84K -363.26K -54.4%
DB Deutsche Bank AG - Registered Shares 1.17M -292.4K -19.9%
Silverarc Capital Management 539.55K +264.21K +96.0%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: American, College, domestic, geopolitical, inflationary, MAD, Poland, pressure, reconcile, Rheumatology
Removed: ASU, Auxilium, charge, Chesterbrook, conform, deemed, Entity, LP, presentation, reclassified, repayment, slowdown, Subtopic